SAB Biotherapeutics (SABS) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Sutro Biopharma (STRO) has outperformed SAB Biotherapeutics (SABS) over the past year, gaining 74.5% versus a gain of 23.1%. Over five years, STRO leads with a -92.3% price change compared with -97.1% for SABS. SAB Biotherapeutics is the larger company by market cap ($262.0 million vs $243.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SABS | STRO |
|---|---|---|
| Share price | $2.88 | $14.66 |
| Market cap | $262.04M | $243.08M |
| 1-day change | -1.71% | +1.45% |
| YTD return | -22.99% | +26.71% |
| 1-year return | +23.08% | +74.52% |
| 5-year return | -97.15% | -92.28% |
| EPS (TTM) | $-1.27 | $-17.28 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.15 | $43.85 |
| 52-week low | $2.10 | $7.15 |
| Distance from 52-week high | -44.08% | -66.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +304.17% | +222.17% |
| Average volume | 486.82K | 289.73K |
| Shares outstanding | 90.99M | 16.58M |
| Employees | 86 | 128 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed SABS by 51.4 percentage points over the past year.
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Healthcare · Biotechnology · 86 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Healthcare · Biotechnology · 128 employees
SABS vs STRO FAQ
Which is bigger, SAB Biotherapeutics or Sutro Biopharma?
SAB Biotherapeutics (SABS) is larger, with a market capitalization of $262.04M compared with $243.08M for Sutro Biopharma (STRO).
Which stock has performed better over the past year, SABS or STRO?
STRO returned +74.52% over the past 12 months, compared with +23.08% for SABS (price return, excluding dividends). Past performance does not predict future results.
Are SAB Biotherapeutics and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.